New PET tracer aims to illuminate hidden HER2 tumors
NCT ID NCT06828588
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tests a radioactive tracer called [68Ga]Ga-ABY-025 for PET scans in 30 adults with advanced HER2-positive cancers (breast, gastric, head/neck, esophageal). Participants receive the tracer and a PET/CT scan before or during standard HER2-targeted therapy. The goal is to see if the tracer safely and clearly highlights tumors, potentially improving how doctors track these cancers.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- [68Ga]Ga-ABY-025 (a radioactive tracer for PET scans)
- What this could lead to
- If successful, this imaging method could help doctors more accurately identify and monitor HER2-positive tumors, potentially guiding treatment decisions.
- What could go wrong
- This is a very early pilot study with only 30 participants, so results are preliminary. The tracer may not improve detection over current methods, and there is a small risk of side effects from the injection.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER 2 LOW-EXPRESSING BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Vanderbilt University Medical Center
RECRUITINGNashville, Tennessee, 37232, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a triple drug combo shrink HER2-Positive breast tumors before surgery?
- Can an extra radiation dose keep HER2+ breast cancer at bay?
- Tissue analysis may guide personalized cancer therapy
- Can a new drug combo shrink Hard-to-Treat salivary gland tumors?
- Can a drug cocktail cure metastatic breast cancer? a trial aims to find out
- Can less chemo be enough? a trial challenges standard treatment for HER2-Positive breast cancer